Authors
Latest:
Current Shortcomings in the Modern Urology Practice Management LandscapeA urologist practicing in California defines the remaining general and region-specific challenges he faces in managing his practice and his hopes for future solutions.
Latest:
Future Directions of BCG-Unresponsive NMIBC ManagementA panelist discusses how urologists considering newer treatment modalities for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) should be encouraged by positive clinical trial data while ensuring proper training, patient selection, and establishment of treatment protocols in their practice.
Latest:
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal TherapyPanelists discuss how managing cognitive and sexual health in prostate cancer patients undergoing hormonal therapy is crucial, emphasizing the need for proactive communication and tailored interventions to enhance overall quality of life.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
Timothy Lyon, MD, highlights study assessing accuracy of urology rankings"The objective of this project [was] to clinically adjudicate the complications identified by that outpatient software," says Timothy D. Lyon, MD.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC ManagementPanelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Latest:
Balancing the benefits and risks of AI in health care“The potential benefits of incorporating AI into health care are numerous but like every technology, AI comes with risks that must be managed if the benefits of these tools are to outweigh the potential costs,” writes cybersecurity expert Jon Moore.
Latest:
Expert shares tips for safeguarding your practice when using telehealthHealth care practitioners utilizing telemedicine, regardless of the modality, must be cognizant of the many pitfalls of violating the rules regulating patient confidentiality as established by federal and state privacy laws.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Latest:
Navigating work-life balance: VUMC’s Family Planning for Surgeons Series"I hope that [attendees] will be exposed to a community where they feel that they're able to freely ask questions, gain accurate information, and feel heard, validated, and connected," says Lauren E. Corona, MD.
Latest:
Jeffrey A. Albaugh, PhD, APRN, CUCNS, on editing the second edition of SUNA’s Core Curriculum"It was a daunting task, although I will say the original core was exceptional, so I had a wonderful framework from which to work," says Jeffrey A. Albaugh, PhD, APRN, CUCNS.
Latest:
UTI vaccine shows efficacy, safety in men and women"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates"I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Investigators highlight real-world data on nadofaragene firadenovec in NMIBC"At 3 months, those patients had a 79% complete response rate, which was durable in 74% at 6 months and 60% at 9 months," says Jacob A. Moyer, BS.
Latest:
Medical software should be chosen based on your practice’s life cycle stageAt each stage, health care providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.
Latest:
Gal Wald, MD: BCG plus gemcitabine shows early efficacy in NMIBC"Overall, our trial shows promising early oncological efficacy with a favorable toxicity profile," says Gal Wald, MD.
Latest:
The current state of adjuvant radiotherapy post prostatectomy: 3 take-home messages"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Latest:
Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.
Latest:
Subgroup data sustain enzalutamide PFS benefit in nmCRPCNo new safety signals were reported with the androgen receptor pathway inhibitor.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Exploring the potential role of ctDNA as a biomarker in kidney cancer"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.
Latest:
FDA testosterone labeling changes: How will they affect prescribing?"In a practice like mine, where approximately 30% of the practice is low testosterone, it'll have actually very little negative effect," says John P. Mulhall, MD.
Latest:
Immune cell discovery offers new potential for cancer immunotherapyWinship study paves the way for more patients to benefit from future immunotherapies.
Latest:
Minimizing incontinence after radical prostatectomy: Lessons learned"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Latest:
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancerAdding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
